Publication:
Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis

dc.contributor.authorRatree Sawangjiten_US
dc.contributor.authorBunchai Chongmelaxmeen_US
dc.contributor.authorPochamana Phisalprapaen_US
dc.contributor.authorSurasak Saokaewen_US
dc.contributor.authorAmmarin Thakkinstianen_US
dc.contributor.authorKris V. Kowdleyen_US
dc.contributor.authorNathorn Chaiyakunapruken_US
dc.contributor.otherMahasarakham Universityen_US
dc.contributor.otherMonash University Malaysiaen_US
dc.contributor.otherNaresuan Universityen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherUniversity of Phayaoen_US
dc.contributor.otherSwedish Medical Centeren_US
dc.contributor.otherUniversity of Wisconsin Madisonen_US
dc.contributor.otherUniversity of Queenslanden_US
dc.date.accessioned2018-12-11T03:33:43Z
dc.date.accessioned2019-03-14T08:02:14Z
dc.date.available2018-12-11T03:33:43Z
dc.date.available2019-03-14T08:02:14Z
dc.date.issued2016-08-01en_US
dc.description.abstractCopyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved. Background: The prevalence of nonalcoholic fatty liver disease (NAFLD) has significantly increased over the last decades. Despite existence of several interventions, there remains unclear which interventions work the best. Methods: A systematic review and network meta-analysis of randomized trials comparing efficacy of all treatment options in NAFLD were performed to determine comparative efficacy and safety of interventions in the management of NAFLD. Several electronic databases were searched up to Nov 15, 2015. Outcomes include liver histological outcomes (i.e., fibrosis), all-cause mortality, cirrhosis, and safety. A network meta-analysis was applied to estimate pooled risk ratios (RR). Quality of evidence was assessed using GRADE criteria. Results: A total of 44 studies (n = 3802) were eligible. When compared with placebo, obeticholic acid (OCA) was the only intervention that significantly improved fibrosis with RR (95% CI) of 1.91 (1.15, 3.16), while pentoxyfylline (PTX) demonstrated improved fibrosis without statistical significance with RR (95% CI) of 2.27 (0.81, 6.36). Only thiazolidinedione (TZD) and vitamin E use resulted in significant increase in resolution of NASH, while OCA, TZD, and vitamin E significantly improved other outcomes including NAS, steatosis, ballooning, and inflammation outcomes. Quality of evidence varied from very low (i.e., metformin, PTX on mean change of ballooning grade) to high (OCA, TZD, vitamin E on improving histological outcomes). Limitations of this study were lack of relevant long-term outcomes (e.g., cirrhosis, death, safety), possible small study effect, and few head-to-head studies. Conclusions: Our study suggests potential efficacy of OCA, TZD, and vitamin E in improving histologic endpoints in NAFLD. These findings are however based on a small number of studies. Additional studies are awaited to strengthen this network meta-analysis.en_US
dc.identifier.citationMedicine (United States). Vol.95, No.32 (2016)en_US
dc.identifier.doi10.1097/MD.0000000000004529en_US
dc.identifier.issn15365964en_US
dc.identifier.issn00257974en_US
dc.identifier.other2-s2.0-84983419781en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/41288
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84983419781&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleComparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysisen_US
dc.typeReviewen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84983419781&origin=inwarden_US

Files

Collections